ClinicalTrials.gg
TerminatedNCT05476783Updated May 6, 2026Results posted

A Long Term Extension Study to Assess the Safety of TB006 in Participants With Alzheimer's Disease

A Phase 2 interventional study of TB006 in Alzheimer's Disease, sponsored by TrueBinding, Inc.. Terminated at 13 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by TrueBinding, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
Resource Constraints

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
119
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,940 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 445 under way, 40 of them phase 3. Alzheimer Disease · United States.

Enrollment
618th of 1,609
119 · median 73
Started
2022
with 130 others
Phase 2
360 of 1,940
50 open now
Registered
1,480th of 1,940
by date

Among the 1,940 studies in Alzheimer Disease with a site in United States, this one is the 618th largest by enrollment of the 1,609 interventional ones that give a count, is one of 131 that started in 2022, is one of 360 in phase 2, and was the 1,480th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,940 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,940 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

This is an open-label long term extension study for participants with Alzheimer's disease (AD) who have completed Protocol TB006AD2102 (lead-in study) or participants who would have been eligible for the lead-in study but were not enrolled (de novo). The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TB006. The total study duration for each participant will be up to 113 weeks.

Read the detailed description

The total study duration for each participant will be up to 113 weeks [This includes 101 weeks (2 years) of dosing and a 12-week safety follow-up period]. The number of participants enrolled from the lead-in study will be 100 to 120 and additionally, up to 50 de novo participants, identified by the sponsor, may be included. A total of approximately 150 to 180 participants will be enrolled.

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

Keywords

  • Alzheimer's disease
  • Open-label Extension
  • TB006
  • TB006AD2102
  • De Novo
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Lead-in study participants are eligible to be included in the study only if they meet the following criteria:

  • Completed lead-in Protocol TB006AD2102 (Participants from both study drug and placebo groups) or are eligible for the lead-in study but were not enrolled (de novo).
  • Eligibility must be reconfirmed by the investigator for participants who have a gap of more than 28 days between lead-in Protocol TB006AD2102 completion and enrolment in the current study. These participants will undergo the screening procedures in the current Open-label extension (OLE) protocol, with the exception of imaging.
  • use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Females must be of non-.
  • Participants or caregiver has the ability to understand the purpose and risks of the study and provide signed and dated . Participants whose caregiver signs the informed consent must provide their assent.
  • Either currently or previously (in pre-AD condition) literate and capable of reading, writing, and communicating effectively with others.
  • Participants, along with the caregiver, will be compliant with study visits, procedure.

De novo participants, identified by the sponsor and referred to a participating site, are eligible to be included in the study only if all of the following criteria apply:

  • Male and/or female > 50 years of age at the time of signing the informed consent.
  • Body weight of ≥ 50 kilograms (kg) and (BMI) between 18 and 35 kilograms per square meter (kg/m\^2), inclusive.
  • score of 24 or less.
  • Must be ambulatory.
  • Clinical diagnosis of AD consistent with the following:

    1. Probable AD, according to National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA).
    2. Meets the , Fifth Edition (DSM-5) - Criteria for Major Neurocognitive Disorder (previously dementia).
  • Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Females must be of non-childbearing potential.
  • Participants or caregiver has the ability to understand the purpose and risks of the study and provide signed and dated informed consent. Participants whose caregiver signs the informed consent must provide their assent.
  • Either currently or previously (in pre-AD condition) literate and capable of reading, writing, and communicating effectively with others.

Exclusion criteria

Exclusion Criteria:

Lead-in study participants are excluded from the study if any of the following criteria apply:

  • Development of an intolerable adverse event or an adverse event that was considered an important safety risk in Protocol TB006AD2102
  • Any of the following emerging medical or psychiatric exclusion criteria as defined in the lead-in Protocol TB006AD2102:

    1. Any medical or neurological condition other than AD that in the opinion of the investigator could be a contributing cause of the Participant's dementia
    2. History within the past 6 months or evidence of psychiatric illness like major depression, schizophrenia, or bipolar affective disorder
    3. Diagnosis of a dementia-related central nervous system (CNS) disease other than AD (eg, Parkinson's Disease, Huntington's Disease, frontotemporal dementia, multi-infarct dementia, dementia with Lewy bodies, or normal pressure hydrocephalus).
    4. Identification of other known cause of dementia or any other clinically significant contributing co-morbid pathologies at screening MRI
    5. Any to having a brain MRI eg, pacemaker; non-MRI compatible aneurysm clips, artificial heart valves, or other metal foreign body; claustrophobia)
    6. Any untreated or unstable clinically significant medical condition like hypertension, diabetes, chronic obstructive pulmonary disorder, asthma, or depression
    7. Any clinically significant findings in medical examination, including physical examination, 12-lead (ECG), clinical laboratory tests.
    8. Undergone major surgery \<= 2 months before study drug administration.
    9. Loss of more than 100 milliliters (mL) blood (eg, a blood donation) within 2 months before first study drug administration, or has received any blood, plasma, or transfusions within 3 months before Day 1, or plans to donate blood during the study or within 3 months after the study.
    10. Regular alcohol consumption within 6 months prior to the study defined as: an average weekly (QW) intake of > 20 units for males or > 16 units for females. One unit is equivalent to 8 grams (g) of alcohol.
    11. Meets criteria for moderate or severe substance use disorder within the past 12 months, or has a positive test for substances of abuse, or has used substances, including but not limited to opiates, methadone, buprenorphine, methamphetamine, cocaine, amphetamines recreationally within the past 12 months.
    12. Unable to complete this study for other reasons or the investigator believes the Participant should be excluded.
  • Since participating in Protocol TB006AD2102, the participant has participated in another drug, biologic, device, or a clinical study or treatment with an drug or approved therapy for investigational use.
  • Any clinically significant findings in medical examination. This includes physical examination, 12-lead ECG, or clinical laboratory tests on the final visit in Protocol TB006AD2102 or on the Baseline visit in this study. Participants who are coronavirus disease of 2019 (COVID-19)-positive at Screening (or end of treatment [EOT] from lead-in study) must delay the start of the study until they are COVID-19-negative. They may be retested at weekly intervals.
  • Participants who have undergone major surgery since enrolment in Protocol TB006AD2102 will be considered on a case-by-basis.

De Novo participants are excluded from the study if any of the following criteria apply:

  • Any medical or neurological condition other than AD that in the opinion of the investigator could be a contributing cause of the participant's dementia
  • History within the past 6 months or evidence of clinically significant psychiatric illness (eg, major depression, schizophrenia, or bipolar affective disorder).
  • Diagnosis of a dementia-related CNS disease other than AD (eg, Parkinson's Disease, Huntington's Disease, frontotemporal dementia, multi-infarct dementia, dementia with Lewy bodies, normal pressure hydrocephalus).
  • Identification of other known cause of dementia or any other clinically significant contributing co-morbid pathologies at screening MRI, in the opinion of the investigator.
  • Participation in any other drug, biologic, device, or clinical study or treatment with any investigational drug or approved therapy for investigational use within 30 days (or 5 half-lives, whichever is longer) prior to screening, and/or participation in any other clinical study involving experimental medications for AD within the 60 days (or 5 half-lives, whichever is longer) prior to screening.
  • Any contraindications to having a brain MRI eg, pacemaker; non-MRI-compatible aneurysm clips, artificial heart valves, or other metal foreign body; claustrophobia).
  • Any untreated or unstable clinically significant medical condition (ie, hypertension, diabetes, chronic obstructive pulmonary disorder, asthma, depression, etc.) as judged by the investigator.
  • Any clinically significant findings in medical examination, including physical examination, 12-lead ECG, clinical laboratory tests.
  • Undergone major surgery \<= 2 months before study drug administration.
  • Loss of more than 100 mL blood (eg, a blood donation) within 2 months before first study drug administration, or has received any blood, plasma, or platelet transfusions within 3 months before Day 1, or plans to donate blood during the study or within 3 months after the study.
  • Recent (3-month) history of a positive COVID-19 test result or disease symptoms of COVID-19 disease such as shortness of breath, cough, rhinorrhea, and sore throat, etc.
  • Known history of, or a positive test result for surface antigen (HBsAg), immunoglobulin M antibody to Hepatitis B core antigen (IgM anti HBc), anti- virus antibodies (HCV), or (HIV) types 1 or 2 at screening. Participants with a documented history of treatment for Hepatitis C are otherwise eligible to participate.
  • Regular alcohol consumption within 6 months prior to the study defined as: an average QW intake of > 20 units for males or > 16 units for females.
  • Meets DSM-5 criteria for moderate or severe substance use disorder within the past 12 months, or has a positive test for substances of abuse, or has used substances, including but not limited to opiates, methadone, buprenorphine, methamphetamine, cocaine, amphetamines recreationally within the past 12 months.
  • Unable to complete this study for other reasons or the investigator believes that he or she should be excluded.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    TB006 4000 mg

    TB006 4000 milligram (mg) via a 1-hour continuous intravenous (IV) infusion will be administered once every 28 day

    Drug: TB006

Interventions

  • DrugTB006

    Clear to slightly opalescent, sterile solution for injection

    Also known as: oloctinebart

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events and Serious Adverse Events

    Summary for Number of Participants with Adverse Events and Serious Adverse Events

    Time frame: Up to 61 weeks

  2. Number of Participants With Clinically Significant Clinical Laboratory Parameter Values

    Summary of participants with Clinically Significant Clinical Laboratory Parameter Values

    Time frame: Up to 61 weeks

  3. Number of Participants With Clinically Significant Vital Sign Values

    Summary of Participants with Clinically Significant Vital Sign Values

    Time frame: Up to 61 weeks

  4. Number of Participants With Clinically Significant 12-Lead Electrocardiogram Findings

    Summary of Participants with Clinically Significant 12-Lead electrocardiogram Findings

    Time frame: Up to 61 weeks

  5. Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a suicidal ideation and behavior rating scale with yes/no responses. For each of the 5 items of the C-SSRS related to suicidal ideation intensity, an individual's degree of suicidal ideation is rated on a 0-5 scale with 0: no suicidal behavior and 5: active suicidal ideation. The total score is the sum of the 5 intensity item scores (total score ranges from 0 to 25). Higher scores in the scale indicate greater disease severity. An increase from baseline in the total score of C-SSRS \>=1 is considered as an adverse change.

    Time frame: Baseline and up to 61 weeks

  6. Plasma Concentration of TB006

    Summary of plasma concentration of TB006

    Time frame: Pre-dose, and Weeks 1, 5, 9, 13, 17, 21, 25, 45, 73, 101, 113 and ED/EOS up to Week 61

  7. Number of Participants With Anti-TB006 Antibodies

    Summary of Participants with Anti-TB006 Antibodies

    Time frame: Up to 61 weeks

Secondary outcomes

  1. Change From Baseline in Clinical Dementia Rating Scale-Sum of Boxes (CDR SB) Score

    The CDR scale is a clinician-rated dementia staging system that tracks the progression of cognitive impairment in 6 categories (memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care). Each category is scored on a 5-point scale in which None = 0, Questionable = 0.5, Mild = 1, Moderate = 2, and Severe = 3. The global CDR score is established by clinical scoring rules and has values of 0 (no dementia), 0.5, (questionable dementia), 1 (mild dementia), 2 (moderate dementia), and 3 (severe dementia). The Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) is obtained by adding the ratings in each of the 6 categories and ranges from 0 to 18 with higher scores indicative of greater impairment.

    Time frame: Baseline and up to Week 101

  2. Change From Baseline in Mini Mental State Examination (MMSE) Score

    Global cognitive functioning is measured by MMSE. MMSE is a neuropsychological test for the evaluation of intellectual efficiency disorders and the presence of cognitive impairment. The total score is between a minimum of 0 (worse cognitive function) and a maximum of 30 points (normal cognitive function). A lower score indicates severe impairment of cognitive abilities and a higher score indicates cognitive normality.

    Time frame: Baseline and up to Week 101

  3. Change From Baseline in Neuropsychiatry Inventory (NPI) Score

    The NPI is a condition-specific measure designed to assess 12 behavioral disturbances, namely delusions, hallucinations, depression/dysphoria, anxiety, agitation/aggression, elation/euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, night-time behavior disturbances, and appetite/eating abnormalities. The frequency is scored from 0 (never) to 4 (very frequently) and severity ranges between 0 (none) to 3 (marked). The domain score is obtained by multiplying frequency and severity scores. The total NPI score is the sum total of all individual domain scores (0-144). A higher score indicates abnormal behaviour.

    Time frame: Baseline and up to Week 101

  4. Change From Baseline in EuroQol 5 Dimension 5-Level Quality of Life (EQ 5D 5L QoL) Total Score

    EuroQol 5 is a self-reported description of participant's current health in 5 dimensions i.e., mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Participants to grade their own current level of function in each dimension into one of three degrees of disability (severe, moderate or none). Score ranges between 1 (no problem) and 3 (significant problem). higher scores indicating higher health utility. The total score is the sum total of all individual domain scores (5-15). Higher scores indicates poor quality of life.

    Time frame: Baseline and up to Week 101

07

Results

Posted May 6, 2026

Participant flow

This study enrolled adult patients who completed the lead-in Protocol TB006AD2102 (patients from both TB006 treatment and placebo groups) or were eligible for the lead-in study but were not enrolled (de novo). A total of 125 patients were screened, of whom 6 (4.8%) patients were screening failures, 119 patients were included in the study. Study Period: Approximately 14 Months Date of First Enrollment: 15 Sep 2022 Date of Last Completed: 17 Nov 2023 Multicenter, 15 sites in the US.

Participant flow — Overall Study
MilestoneTB006 4000 mg
Started119
Completed0
Not completed119
Withdrew: This was a business decision, and not due to safety or efficacy concerns108
Withdrew: Withdrawal by subject5
Withdrew: Lost to follow-up2
Withdrew: Adverse event1
Withdrew: Death1
Withdrew: Physician decision1
Withdrew: Other, not specified1

Outcome measures

PrimaryNumber of Participants With Adverse Events and Serious Adverse Events

Summary for Number of Participants with Adverse Events and Serious Adverse Events

Time frame:
Up to 61 weeks
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events and Serious Adverse Events
ParticipantsTB006 4000 mg
Adverse Events58
No Adverse Events61
PrimaryNumber of Participants With Clinically Significant Clinical Laboratory Parameter Values

Summary of participants with Clinically Significant Clinical Laboratory Parameter Values

Time frame:
Up to 61 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Clinical Laboratory Parameter Values
ParticipantsTB006 4000 mg
Clinically Significant Labs Reported0
No Clinically Significant Labs Reported119
PrimaryNumber of Participants With Clinically Significant Vital Sign Values

Summary of Participants with Clinically Significant Vital Sign Values

Time frame:
Up to 61 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Sign Values
ParticipantsTB006 4000 mg
Significant (meaningful) Vital Sign Changes0
No Significant (meaningful) Vital Sign Changes119
PrimaryNumber of Participants With Clinically Significant 12-Lead Electrocardiogram Findings

Summary of Participants with Clinically Significant 12-Lead electrocardiogram Findings

Time frame:
Up to 61 weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant 12-Lead Electrocardiogram Findings
ParticipantsTB006 4000 mg
Clinically Significant (meaningful) 12-Lead electrocardiogram Changes0
No Clinically Significant (meaningful) 12-Lead electrocardiogram Changes119
PrimaryChange From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS)

The C-SSRS is a suicidal ideation and behavior rating scale with yes/no responses. For each of the 5 items of the C-SSRS related to suicidal ideation intensity, an individual's degree of suicidal ideation is rated on a 0-5 scale with 0: no suicidal behavior and 5: active suicidal ideation. The total score is the sum of the 5 intensity item scores (total score ranges from 0 to 25). Higher scores in the scale indicate greater disease severity. An increase from baseline in the total score of C-SSRS \>=1 is considered as an adverse change.

Time frame:
Baseline and up to 61 weeks
Reported as:
Count of participants · Participants
Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsTB006 4000 mg
Number of patients with an adverse change from baseline in C-SSRS1
Number of patients with no change from baseline in C-SSRS118
PrimaryPlasma Concentration of TB006

Summary of plasma concentration of TB006

Time frame:
Pre-dose, and Weeks 1, 5, 9, 13, 17, 21, 25, 45, 73, 101, 113 and ED/EOS up to Week 61
Reported as:
Mean · μg/mL
Plasma Concentration of TB006
μg/mLTB006 4000 mg
Week 1 PK concentration70.97 ± 288.97
Week 5 PK concentration412.91 ± 131.78
Week 9 PK concentration615.86 ± 257.17
Week 13 PK concentration694.85 ± 334.03
Week 17 PK concentration733.19 ± 298.13
Week 21 PK concentration791.79 ± 313.83
Week 25 PK concentration852.00 ± 389.09
ED/EOS PK concentration382.56 ± 366.55
PrimaryNumber of Participants With Anti-TB006 Antibodies

Summary of Participants with Anti-TB006 Antibodies

Time frame:
Up to 61 weeks
Reported as:
Count of participants · Participants
Number of Participants With Anti-TB006 Antibodies
ParticipantsTB006 4000 mg
ADA positive at end of study; No evidence of an altered safety profile in positive patients.9
ADA negative patients at end of study110
SecondaryChange From Baseline in Clinical Dementia Rating Scale-Sum of Boxes (CDR SB) Score

The CDR scale is a clinician-rated dementia staging system that tracks the progression of cognitive impairment in 6 categories (memory, orientation, judgement and problem solving, community affairs, home and hobbies, and personal care). Each category is scored on a 5-point scale in which None = 0, Questionable = 0.5, Mild = 1, Moderate = 2, and Severe = 3. The global CDR score is established by clinical scoring rules and has values of 0 (no dementia), 0.5, (questionable dementia), 1 (mild dementia), 2 (moderate dementia), and 3 (severe dementia). The Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) is obtained by adding the ratings in each of the 6 categories and ranges from 0 to 18 with higher scores indicative of greater impairment.

Time frame:
Baseline and up to Week 101
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Dementia Rating Scale-Sum of Boxes (CDR SB) Score
units on a scaleTB006 4000 mg
Change From Baseline in Clinical Dementia Rating Scale-Sum of Boxes (CDR SB) Score0.12 ± 1.606
SecondaryChange From Baseline in Mini Mental State Examination (MMSE) Score

Global cognitive functioning is measured by MMSE. MMSE is a neuropsychological test for the evaluation of intellectual efficiency disorders and the presence of cognitive impairment. The total score is between a minimum of 0 (worse cognitive function) and a maximum of 30 points (normal cognitive function). A lower score indicates severe impairment of cognitive abilities and a higher score indicates cognitive normality.

Time frame:
Baseline and up to Week 101
Reported as:
Mean · units on a scale
Change From Baseline in Mini Mental State Examination (MMSE) Score
units on a scaleTB006 4000 mg
Change From Baseline in Mini Mental State Examination (MMSE) Score-0.9 ± 3.22
SecondaryChange From Baseline in Neuropsychiatry Inventory (NPI) Score

The NPI is a condition-specific measure designed to assess 12 behavioral disturbances, namely delusions, hallucinations, depression/dysphoria, anxiety, agitation/aggression, elation/euphoria, disinhibition, irritability/lability, apathy, aberrant motor activity, night-time behavior disturbances, and appetite/eating abnormalities. The frequency is scored from 0 (never) to 4 (very frequently) and severity ranges between 0 (none) to 3 (marked). The domain score is obtained by multiplying frequency and severity scores. The total NPI score is the sum total of all individual domain scores (0-144). A higher score indicates abnormal behaviour.

Time frame:
Baseline and up to Week 101
Reported as:
Mean · units on a scale
Change From Baseline in Neuropsychiatry Inventory (NPI) Score
units on a scaleTB006 4000 mg
Change From Baseline in Neuropsychiatry Inventory (NPI) Score1.4 ± 13.44
SecondaryChange From Baseline in EuroQol 5 Dimension 5-Level Quality of Life (EQ 5D 5L QoL) Total Score

EuroQol 5 is a self-reported description of participant's current health in 5 dimensions i.e., mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Participants to grade their own current level of function in each dimension into one of three degrees of disability (severe, moderate or none). Score ranges between 1 (no problem) and 3 (significant problem). higher scores indicating higher health utility. The total score is the sum total of all individual domain scores (5-15). Higher scores indicates poor quality of life.

Time frame:
Baseline and up to Week 101
Reported as:
Mean · units on a scale
Change From Baseline in EuroQol 5 Dimension 5-Level Quality of Life (EQ 5D 5L QoL) Total Score
units on a scaleTB006 4000 mg
For Patient2.1 ± 13.06
For Caregiver2.2 ± 17.72

Adverse events

Collected over All Adverse Events (AEs) were collected from the time of the first study drug administration until Week 61 at the time points specified in the Schedule of Events.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TB006 4000 mg2/119 (1.7%)9/119 (7.6%)37/119 (31.1%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventTB006 4000 mg
Arteriosclerosis coronary arteryCardiac disorders1/119
Atrial flutterCardiac disorders1/119
Myocardial infarctionCardiac disorders1/119
AstheniaGeneral disorders1/119
InfluenzaInfections and infestations1/119
Pneumococcal sepsisInfections and infestations1/119
Rhinovirus infectionInfections and infestations1/119
Urinary tract infectionInfections and infestations1/119
FallInjury, poisoning and procedural complications1/119
EncephalopathyNervous system disorders1/119
Most frequent other events
Most frequent other events
EventTB006 4000 mg
Urinary tract infectionInfections and infestations7/119
FallInjury, poisoning and procedural complications7/119
COVID-19Infections and infestations6/119
Blood pressure increasedInvestigations5/119
Upper respiratory tract infectionInfections and infestations3/119
SyncopeNervous system disorders3/119
AgitationPsychiatric disorders3/119
DepressionPsychiatric disorders3/119

Baseline characteristics

Age, Continuous
Age, Continuous(years)TB006 4000 mg
Mean73.2 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)TB006 4000 mg
Female68
Male51
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TB006 4000 mg
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American13
White104
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(participants)TB006 4000 mg
United States119
Diagnosis of Alzheimers Disease
Diagnosis of Alzheimers Disease(Participants)TB006 4000 mg
Count of participants119
08

Study locations

13 sites
  • Clinical Trial Site
    San Diego, California 92103, United States
  • Clinical Trial Site
    Delray Beach, Florida 33445, United States
  • Clinical Trial Site
    Lady Lake, Florida 32159, United States
  • Clinical Trial Site
    Maitland, Florida 32751, United States
  • Clinical Trial Site
    Miami, Florida 33135, United States
  • Clinical Trial Site
    Miami, Florida 33137, United States
  • Clinical Trial Site
    Miami, Florida 33165, United States
  • Clinical Trial Site
    West Palm Beach, Florida 33407, United States
  • Clinical Trial Site
    Winter Park, Florida 32789, United States
  • Clinical Trial Site
    Winter Park, Florida 32792, United States
  • Clinical Trial Site
    Decatur, Georgia 30030, United States
  • Clinical Trial Site
    Matthews, North Carolina 28105, United States
  • Clinical Trial Site
    Fairfax, Virginia 22031, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Nov 2023, 14 months.

Results were first posted in May 2026, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2022
First posted
Jul 27, 2022
StartActual
Sep 15, 2022
Primary completionActual
Nov 17, 2023
CompletionActual
Nov 17, 2023
Results first posted
May 6, 2026
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05476783
Lead sponsor
TrueBinding, Inc.
Responsible party
Sponsor
First posted
Jul 27, 2022
Start date
Sep 15, 2022
Primary completion
Nov 17, 2023
Completion
Nov 17, 2023
Results posted
May 6, 2026
Last update
May 6, 2026

Study contacts

Alan K Jacobs, MD
study director · TrueBinding, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TB006

Start the discussion